Illumina (NASDAQ:ILMN) Price Target Lowered to $136.00 at Morgan Stanley

Illumina (NASDAQ:ILMN) had its price objective decreased by Morgan Stanley from $150.00 to $136.00 in a report published on Tuesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the life sciences company’s stock.

Other analysts have also issued research reports about the stock. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and lowered their target price for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Canaccord Genuity Group lowered their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. Stephens lifted their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Guggenheim lowered their target price on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Stock Performance

Shares of Illumina stock opened at $100.68 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market cap of $15.97 billion, a P/E ratio of -13.11 and a beta of 1.10. The firm has a 50 day simple moving average of $135.90 and a 200 day simple moving average of $135.48. Illumina has a fifty-two week low of $100.08 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Sell-side analysts predict that Illumina will post 4.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC lifted its position in Illumina by 24.6% in the 4th quarter. LPL Financial LLC now owns 82,867 shares of the life sciences company’s stock valued at $11,073,000 after acquiring an additional 16,339 shares in the last quarter. Guardian Partners Inc. bought a new stake in Illumina in the 4th quarter valued at $2,537,000. KLP Kapitalforvaltning AS bought a new stake in Illumina during the 4th quarter worth about $8,051,000. Sei Investments Co. lifted its position in Illumina by 3.6% during the 4th quarter. Sei Investments Co. now owns 134,913 shares of the life sciences company’s stock worth $18,028,000 after buying an additional 4,738 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Illumina by 11.5% during the 4th quarter. American Century Companies Inc. now owns 226,852 shares of the life sciences company’s stock worth $30,314,000 after buying an additional 23,338 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.